N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2031

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

DRUG

N803

N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles.

Trial Locations (1)

Huntsman Cancer Institute at University of Utah, Salt Lake City